41
Participants
Start Date
March 23, 2018
Primary Completion Date
July 17, 2019
Study Completion Date
July 17, 2019
Murepavadin
Murepavadin IV every 8 hours + 1 anti-pseudomonal antibiotic (Piperacillin-tazobactam, ceftazidine, cefepime, meropenem, amikacin, ciprofoxacin, levofloxacin, colistin)
Two anti-pseudomonal antibiotics
Piperacillin-tazobactam, ceftazidine, cefepime, meropenem, amikacin, ciprofoxacin, levofloxacin, colistin
Research site, Greensboro
Research site, Chicago
Research site, Springfield
Research Site 1, Belo Horizonte
Research Site 2, Belo Horizonte
Research Site, Itaquaquecetuba
Research Site, Porto Alegre
Research Site, São José do Rio Preto
Research site 1, Zagreb
Research site 2, Zagreb
Research site, Tallinn
Reasearch site, Tartu
Reasearch site, Võru
Research site, Lille
Reasearch site, Limoges
Research site, Lyon
Reasearch site, Nice
Research site 1, Paris
Research site 2, Paris
Research site 3, Paris
Research site, Pierre-Bénite
Research Site, Athens
Research Site, Ioannina
Research Site 1, Larissa
Research Site 2, Larissa
Research Site, Pátrai
Research Site, Thessaloniki
Reasearch site, Budapest
Research site, Budapest
Reasearch site, Ózd
Research Site, Kistarcsa
Research Site, Székesfehérvár
Research Site, Vác
Research site, Jerusalem
Research site, Nahariya
Research site, Tiberias
Research site, Petah Tikva
Research site, Safed
Research site, Tel Litwinsky
Research Site 1, Guadalajara
Research Site 2, Guadalajara
Research Site, Monterrey
Research site 1, Pretoria
Research Site, Cape Town
Research Site 2, Pretoria
Research Site, Pretoria
Research Site, Ansansi Danweongu
Research Site, Gangwon-do
Research site, Gyeongsang
Research site, Incheon
Research site 1, Seoul
Research site 2, Seoul
Research Site 3, Seoul
Research site, Seoul
Research site, Barcelona
Research site, Terrassa
Research site, Girona
Research Site 1, Bangkok
Research Site 2, Bangkok
Research Site, Khon Kaen
Research Site, Nonthaburi
Lead Sponsor
Polyphor Ltd.
INDUSTRY